**Question:** Treatment of leprosy according to WHO is done by all drugs, except

A. Dapsone
B. Clofazimine
C. Benzathine Penicillin
D. Ofloxacin

**Core Concept:** Leprosy is a chronic infectious disease caused by Mycobacterium leprae or M. leprae. The World Health Organization (WHO) has recommended a standardized treatment protocol for leprosy patients, known as the "2011 WHO Multidrug Therapy (MDT)."

**Why the Correct Answer is Right:** The correct answer, D. Ofloxacin, is excluded from the WHO recommended MDT regimen because it is not a primary component of the treatment protocol. The MDT regimen comprises three main drugs:

1. Clofazimine: A lipophilic drug that exhibits bactericidal activity against M. leprae and M. lepromatosis. It targets the bacterial cell wall and is effective against both acid-fast and non-acid-fast bacilli.
2. Dapsone: A sulfonamide antibiotic that inhibits the enzyme dihydropteroate synthetase, an essential enzyme for bacterial growth. It also has immunomodulatory effects and has been shown to reduce the severity and frequency of skin lesions in leprosy patients.
3. Rifampicin: A bactericidal antibiotic that inhibits RNA synthesis in bacteria. It also has immunomodulatory effects, enhancing the host's immune response against M. leprae and M. lepromatosis.

**Why Each Wrong Option is Incorrect:**

A. Clofazimine: Included in the WHO-recommended MDT regimen, clofazimine is effective against both acid-fast and non-acid-fast bacilli, targeting the bacterial cell wall.

B. Dapsone: Although dapsone has immunomodulatory effects and can reduce skin lesions in leprosy patients, it is not the only drug in the WHO-recommended regimen.

C. Benzathine Penicillin: While effective against some Mycobacterium species, Benzathine Penicillin is not a part of the WHO-recommended MDT regimen for leprosy treatment.

D. Ofloxacin: Ofloxacin is not included in the WHO-recommended MDT regimen for leprosy treatment. It is a fluoroquinolone antibiotic with broad-spectrum activity against Gram-positive and Gram-negative bacteria. However, it is not used in the WHO-recommended MDT regimen for leprosy treatment.

**Clinical Pearls:**

- The WHO-recommended MDT regimen for leprosy treatment is crucial for effective control of the disease and prevention of drug resistance.
- Ensuring the correct administration of the recommended drugs and understanding the rationale behind each drug choice is essential for proper patient management.
- The standardized treatment regimen helps to prevent the emergence of drug-resistant strains of M. leprae and promotes successful treatment outcomes for leprosy